SAN DIEGO, Jan. 8 /PRNewswire/ -- PacificGMP, Inc., and MediVas, LLC, announced today that they have formed a collaborative effort to develop a commercial scale production process for MediVas’ next generation subunit vaccine utilizing MediVas’s novel amino acid-based Poly(Ester Amide) copolymers (PEA). MediVas’ polymers are the first of a new generation of absorbable and biocompatible drug and biologic delivery platforms. Under this collaboration, PacificGMP will work with MediVas in developing the capability of manufacturing large quantities of subunit vaccines to protect against such diseases as seasonal and pandemic influenza, among many other potential candidates.
PacificGMP will utilize its expertise in disposable bioprocessing and its unique technology to scale up the production process and manufacturing for MediVas’ initial candidates. Use of this disposable bioprocessing technology will allow for faster production, with greatly reduced overall manufacturing costs. This process also mitigates the possibility for cross-contamination in production which should ultimately result in vaccines that will be available to the public in a much shorter time period.
MediVas’ infectious disease and immunology platforms include rapid response formulations for next generation vaccines. MediVas’ lead preventative vaccine program represents a novel process to develop and manufacture vaccines for both seasonal and pandemic influenza. In addition, the Company is also developing therapeutic vaccines with a lead program targeted against certain cancers.
“We continue to advance our capabilities in developing important next-generation biocompatible drug delivery solutions,” said Kenneth Carpenter, President and CEO of MediVas. “We are confident in our ability to create innovative new drug delivery technologies across multiple therapeutic areas. PacificGMP is ideally suited to allow us to take the next step and bring our new therapeutic technology into the clinic and then into the public sphere.”
“PacificGMP is excited to assist MediVas with this important project. We anticipate that production of MediVas’ subunit vaccines in disposable closed systems will be a significant milestone in the development of rapid response formulations for next generation vaccines. We are delighted to announce this collaboration and to assist MediVas in moving forward with this novel technology,” said Leigh Pierce, President of PacificGMP.
About MediVas: Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed a next-generation platform for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world’s largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements. The more than $50 billion biologics market is the next frontier in medicine and MediVas is uniquely poised to take advantage of this growing space. By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unimaginable, such as oral, intranasal, inhaled or subcutaneous injection, can become a reality. By opening up these delivery routes, MediVas’ delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health.
About PacificGMP: PacificGMP is a Contract Manufacturing Organization (CMO) that specializes in the development and manufacturing of biologics using disposable technology. PacificGMP has extensive experience in process development and production of antibodies, recombinant proteins, gene therapy and vaccine products. PacificGMP assists drug developers through the early stages of process design, development and scale-up, to pre-clinical and clinical manufacturing.
For PacificGMP: Gary L. Pierce, General Counsel, PacificGMP 1-858-550-4094, info@pacificgmp.com For MediVas: Victor Vilaplana, Director, Business Development MediVas, LLC 1-858-622-2005 vvilaplana@MediVas.com
PacificGMP, Inc.
CONTACT: Gary L. Pierce, General Counsel of PacificGMP, +1-858-550-4094,info@pacificgmp.com; or Victor Vilaplana, Director, Business Development ofMediVas, LLC, +1-858-622-2005, vvilaplana@MediVas.com
